Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

NCT02465515 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

9463

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

BIOLOGICAL: Albiglutide 30 mg
BIOLOGICAL: Albiglutide 50 mg
BIOLOGICAL: Albiglutide matching placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]